Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have emerged as one of the most promising platforms in oncology drug development. However, even clinically successful ADCs rarely maintain long-term tumor control when used as single agents. The reason is not simply insufficient drug potency. Tumors possess remarkable adaptive capacity and can gradually evade ADC-mediated cytotoxicity through mechanisms such as antigen downregulation, altered internaliza